Lotus Pharmaceutical Co., Ltd. (TPE:1795)
Taiwan
· Delayed Price · Currency is TWD 258.50
+5.00 (1.97%)
Mar 10, 2026, 1:30 PM CST
Lotus Pharmaceutical Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 9, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 66,665 | 71,524 | 71,935 | 64,462 | 25,569 | 19,628 | Upgrade
|
| Market Cap Growth | -10.13% | -0.57% | 11.59% | 152.11% | 30.27% | -29.79% | Upgrade
|
| Enterprise Value | 73,412 | 80,276 | 81,666 | 71,660 | 30,851 | 25,397 | Upgrade
|
| Last Close Price | 253.50 | 262.47 | 260.17 | 232.56 | 90.84 | 74.29 | Upgrade
|
| PE Ratio | 14.05 | 14.12 | 17.52 | 21.34 | 18.22 | 19.12 | Upgrade
|
| Forward PE | 9.61 | 12.05 | 15.36 | 18.39 | 15.41 | 16.33 | Upgrade
|
| PS Ratio | 3.57 | 3.85 | 4.24 | 4.41 | 2.02 | 1.83 | Upgrade
|
| PB Ratio | 3.01 | 3.38 | 4.15 | 4.65 | 2.31 | 2.24 | Upgrade
|
| P/TBV Ratio | 6.66 | 7.26 | 11.65 | 28.14 | 10.18 | - | Upgrade
|
| P/FCF Ratio | 9.09 | 12.33 | 59.77 | 20.52 | - | 12.79 | Upgrade
|
| P/OCF Ratio | 8.68 | 11.62 | 44.56 | 17.33 | 213.68 | 10.07 | Upgrade
|
| EV/Sales Ratio | 3.93 | 4.32 | 4.82 | 4.90 | 2.44 | 2.37 | Upgrade
|
| EV/EBITDA Ratio | 10.50 | 10.95 | 13.23 | 14.07 | 9.63 | 10.74 | Upgrade
|
| EV/EBIT Ratio | 13.13 | 12.99 | 16.07 | 16.86 | 12.20 | 14.59 | Upgrade
|
| EV/FCF Ratio | 10.01 | 13.84 | 67.85 | 22.81 | - | 16.55 | Upgrade
|
| Debt / Equity Ratio | 0.56 | 0.65 | 0.67 | 0.64 | 0.63 | 0.78 | Upgrade
|
| Debt / EBITDA Ratio | 1.78 | 1.83 | 1.84 | 1.72 | 2.12 | 2.80 | Upgrade
|
| Debt / FCF Ratio | 1.69 | 2.36 | 9.63 | 2.84 | - | 4.45 | Upgrade
|
| Net Debt / Equity Ratio | 0.30 | 0.36 | 0.57 | 0.50 | 0.48 | 0.61 | Upgrade
|
| Net Debt / EBITDA Ratio | 0.98 | 1.04 | 1.59 | 1.36 | 1.67 | 2.26 | Upgrade
|
| Net Debt / FCF Ratio | 0.92 | 1.32 | 8.15 | 2.21 | -11.78 | 3.48 | Upgrade
|
| Asset Turnover | 0.49 | 0.51 | 0.54 | 0.58 | 0.62 | 0.56 | Upgrade
|
| Inventory Turnover | 1.97 | 2.01 | 2.13 | 2.13 | 2.65 | 3.45 | Upgrade
|
| Quick Ratio | 1.30 | 1.63 | 1.85 | 1.17 | 1.16 | 0.88 | Upgrade
|
| Current Ratio | 1.81 | 2.15 | 2.80 | 1.81 | 1.93 | 1.39 | Upgrade
|
| Return on Equity (ROE) | 22.32% | 26.30% | 26.32% | 24.23% | 14.16% | 12.48% | Upgrade
|
| Return on Assets (ROA) | 9.09% | 10.57% | 10.16% | 10.47% | 7.71% | 5.73% | Upgrade
|
| Return on Invested Capital (ROIC) | 15.80% | 17.59% | 17.05% | 17.51% | 12.44% | 9.85% | Upgrade
|
| Return on Capital Employed (ROCE) | 18.20% | 19.50% | 17.90% | 18.00% | 15.00% | 11.70% | Upgrade
|
| Earnings Yield | 7.10% | 7.08% | 5.71% | 4.69% | 5.49% | 5.23% | Upgrade
|
| FCF Yield | 11.00% | 8.11% | 1.67% | 4.88% | -1.77% | 7.82% | Upgrade
|
| Dividend Yield | 2.16% | 2.20% | 1.79% | 1.49% | 2.13% | 0.47% | Upgrade
|
| Payout Ratio | 32.12% | 24.32% | 22.07% | 16.75% | 6.56% | - | Upgrade
|
| Buyback Yield / Dilution | 0.26% | -0.53% | -0.13% | -1.95% | -5.43% | -0.65% | Upgrade
|
| Total Shareholder Return | 2.41% | 1.68% | 1.66% | -0.46% | -3.30% | -0.18% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.